A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT07680764

Public ClinicalTrials.gov record NCT07680764. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study identification

NCT ID: NCT07680764
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Interventions

Pumitamig Drug
Imzokitug Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 14, 2026
Primary completion: Sep 14, 2028
Completion: Sep 14, 2030
Last update posted: Jul 23, 2026

2026 – 2030

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Local Institution - 0170	Athens	Georgia	30607	Not yet recruiting
Local Institution - 0034	Lexington	Kentucky	40503	Not yet recruiting
Local Institution - 0171	Lexington	Kentucky	40509	Not yet recruiting
Local Institution - 0123	Baltimore	Maryland	21224	Not yet recruiting
Local Institution - 0180	Hattiesburg	Mississippi	39401	Not yet recruiting
Nebraska Cancer Specialists	Grand Island	Nebraska	68803	Recruiting
Oncology Hematology West PC	Omaha	Nebraska	68130	Recruiting
Local Institution - 0080	New York	New York	10021	Not yet recruiting
Local Institution - 0105	Nashville	Tennessee	37212	Not yet recruiting
Local Institution - 0095	Houston	Texas	77030	Not yet recruiting
Local Institution - 0135	Madison	Wisconsin	53792	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07680764, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 23, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07680764 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →